CVE-2021-3479

Description

There's a flaw in OpenEXR's Scanline API functionality in versions before 3.0.0-beta. An attacker who is able to submit a crafted file to be processed by OpenEXR could trigger excessive consumption of memory, resulting in an impact to system availability.

Categories

5.5
CVSS
Severity: Medium
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.10%
Vendor Advisory gentoo.org
Affected: n/a OpenEXR
Published at:
Updated at:

References

Link Tags
https://bugzilla.redhat.com/show_bug.cgi?id=1939149 issue tracking third party advisory patch
https://bugs.chromium.org/p/oss-fuzz/issues/detail?id=25370 issue tracking third party advisory
https://lists.debian.org/debian-lts-announce/2021/07/msg00001.html third party advisory mailing list
https://security.gentoo.org/glsa/202107-27 third party advisory vendor advisory
https://lists.debian.org/debian-lts-announce/2022/12/msg00022.html third party advisory mailing list

Frequently Asked Questions

What is the severity of CVE-2021-3479?
CVE-2021-3479 has been scored as a medium severity vulnerability.
How to fix CVE-2021-3479?
To fix CVE-2021-3479, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2021-3479 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2021-3479 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2021-3479?
CVE-2021-3479 affects n/a OpenEXR.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.